Document Detail


Regression of renal vascular fibrosis by endothelin receptor antagonism.
MedLine Citation:
PMID:  11230324     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In previous studies, we have observed that endothelin participates in the progression of renal vascular and glomerular fibrosis during hypertension by activating collagen I gene synthesis. The present study investigated whether administration of endothelin receptor antagonists leads to the regression of renal sclerotic lesions. Experiments were performed in transgenic mice harboring the luciferase gene under the control of the collagen I-alpha2 chain promoter. Hypertension was induced by long-term inhibition of nitric oxide synthesis by N(G)-nitro-L-arginine methyl ester (L-NAME); systolic pressure gradually increased, reaching a plateau of 165 mm Hg after 10 weeks of hypertensive treatment. At the same time, collagen I gene expression was increased 2- and 5-fold compared with control animals in afferent arterioles and glomeruli, respectively (P<0.01). This increase was accompanied by the appearance of sclerotic lesions within the renal vasculature. When renal vascular lesions had been established (20 weeks of L-NAME), animals were divided into 2 subgroups: the one continued to receive L-NAME, whereas in the other, bosentan, a dual endothelin antagonist, was coadministered with L-NAME for an additional period of 10 weeks. Bosentan coadministration did not alter the increased systolic pressure at 30 weeks; in contrast, collagen I gene activity returned almost to control levels in renal vessels and glomeruli. In this subgroup of animals, renal vascular lesions (collagen and/or extracellular matrix deposition) and mortality rates were substantially reduced compared with untreated mice. These data indicate that endothelin participates in the mechanism(s) of renal vascular fibrosis by activating collagen I gene. Treatment with an endothelin antagonist normalizes expression of collagen I gene and leads to the regression of renal vascular fibrosis and to the improvement of survival, thus providing a complementary curative approach against renal fibrotic complications associated with hypertension.
Authors:
J J Boffa; P L Tharaux; J C Dussaule; C Chatziantoniou
Related Documents :
22560124 - Expert consensus: renal denervation for the treatment of hypertension.
23009134 - The ajt report: news and issues that affect organ and tissue transplantation.
1854764 - Long-term preservation of renal function in hypertensive heart transplant recipients tr...
17006264 - Can renal leukemic infiltration cause hypertension in children?
24009284 - Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advance...
8827904 - Advances in the clinical management of pediatric kidney transplantation.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hypertension     Volume:  37     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-03-20     Completed Date:  2001-04-26     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  490-6     Citation Subset:  IM    
Affiliation:
INSERM U.489, Hôpital Tenon, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antihypertensive Agents / pharmacology
Blood Pressure
Collagen / biosynthesis,  genetics
Collagen Type I
Endothelins / antagonists & inhibitors*,  physiology
Fibrosis
Gene Expression Regulation
Hypertension, Renovascular / chemically induced,  pathology,  prevention & control*
Kidney Glomerulus / pathology
Luciferases / genetics
Male
Mice
Mice, Transgenic
NG-Nitroarginine Methyl Ester
Perfusion
Receptors, Endothelin / antagonists & inhibitors*
Renal Artery / metabolism,  pathology*
Staining and Labeling
Sulfonamides / administration & dosage,  pharmacology
Time Factors
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Collagen Type I; 0/Endothelins; 0/Receptors, Endothelin; 0/Sulfonamides; 0/alpha 2(I) collagen; 50903-99-6/NG-Nitroarginine Methyl Ester; 9007-34-5/Collagen; EC 1.13.12.-/Luciferases; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in...
Next Document:  Endothelin-1 enhances eicosanoids-induced coronary smooth muscle contraction by activating specific ...